The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.
 
Andres Poveda
Consulting or Advisory Role - AstraZeneca; Immunogen; Novartis; Roche
Travel, Accommodations, Expenses - PharmaMar
 
Ana Oaknin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Ignacio Romero
Consulting or Advisory Role - AstraZeneca; Roche
Speakers' Bureau - AstraZeneca; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Angel Guerrero
No Relationships to Disclose
 
Lorena Fariñas-Madrid
No Relationships to Disclose
 
Victor Rodriguez-Freixinos
No Relationships to Disclose
 
Arturo Soto-Matos
Employment - PharmaMar
Stock and Other Ownership Interests - PharmaMar
Honoraria - PharmaMar
 
Carlos Peris
No Relationships to Disclose
 
Marisa Teruel
No Relationships to Disclose
 
Raquel Lopez-Reig
No Relationships to Disclose
 
Jose Antonio Lopez-Guerrero
No Relationships to Disclose